EYEN-510, EYEN-520, EYEN-530, and others (Dry Eye)

Dry Eye Disease is a common ocular condition and is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film and accompanied by ocular symptoms, such as discomfort and visual disturbance¹.

EYEN-510 is a combination product collaboration between SGN Nanopharma’s micellar nanoparticle cyclosporine formulation, SGN-101, and the Optejet® for the treatment of chronic dry eye disease.

EYEN-520 is a combination product collaboration between Senju’s SJP-0035 formulation, fonadlepar, a peroxisome proliferator-activated receptor delta agonist for the adjunctive treatment of chronic dry eye disease, administered using the Optejet^®.

EYEN-530 is a combination product collaboration between Formosa Pharmaceuticals’ formulation of clobetasol propionate ophthalmic suspension 0.05% and the Optejet for the short-term relief of dry eye disease. Clobetasol propionate is a potent steroid that was approved by the U.S. FDA on March 4, 2024, for the reduction of post-surgical inflammation and pain.

Eyenovia is evaluating other potential dry eye candidates for development in combination with the Optejet. Using the Optejet, dry eye sufferers will conveniently be able to dose themselves with their dry eye medication.

U.S. Addressable Market $5.5B

1. Jennifer P. Craig, et al., TFOS DEWS II Definition and Classification Report, The Ocular Surface, Volume 15, Issue 3, 2017, Pages 276-283